title: Monoclonal antibody therapeutics: history and future.
abstract: Over the last three decades, monoclonal antibodies have made a dramatic transformation from scientific tools to powerful human therapeutics. At present, approximately 30 therapeutic monoclonal antibodies are marketed in the United States and Europe in a variety of indications, with sales in the US alone reaching approximately $18.5 billion in 2010. This review describes how antibody engineering has revolutionized drug discovery and what are considered the key areas for future development in the monoclonal antibody therapy field.
authors.affiliation: Biologics Safety Assessment, MedImmune, Granta Park, Cambridge CB21 6GH, UK. bussn@medimmune.com
authors.forename: Nicholas A P S
authors.initials: NA
authors.lastname: Buss
authors.forename: Simon J
authors.initials: SJ
authors.lastname: Henderson
authors.forename: Mary
authors.initials: M
authors.lastname: McFarlane
authors.forename: Jacintha M
authors.initials: JM
authors.lastname: Shenton
authors.forename: Lolke
authors.initials: L
authors.lastname: de Haan
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology* / Q000627:therapeutic use*; D055808:Drug Discovery / Q000379:methods; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D015202:Protein Engineering / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal